NASDAQ:CHMA
Delisted
Chiasma Stock News
$3.76
+0 (+0%)
At Close: May 27, 2022
Chiasma Reports First Quarter Financial Results and Announced Agreement to Merge with Amryt
07:05am, Wednesday, 05'th May 2021
Announced agreement to merge with Amryt
CHMA Stock Price Increases Over 10% Pre-Market: Why It Happened
05:49am, Tuesday, 23'rd Mar 2021
The stock price of Chiasma Inc (NASDAQ: CHMA) increased by over 10% pre-market. This is why it happened.
--93% of all patients who enrolled as a responder to MYCAPSSA ® maintained their biochemical response at the end of the 48-week open-label extension (OLE) period-- --Safety profile during the OLE was
Chiasma Presents New Positive Data for MYCAPSSA from Phase 3 Trial MPOWERED™ for the Maintenance Treatment of Acromegaly at ENDO 2021
11:00am, Saturday, 20'th Mar 2021
--Data supports MYCAPSSA® as non-inferior to long-acting injectable somatostatin receptor ligands (iSRLs)-- --Data demonstrated patients taking MYCAPSSA had significant improvement in acromegaly rela
Chiasma to Present New Data from Two Phase 3 Trials, CHIASMA OPTIMAL and MPOWERED™, at ENDO 2021
08:00am, Wednesday, 10'th Mar 2021
-- One oral presentation and five late-breaking posters accepted -- NEEDHAM, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-
Chiasma, Inc. (CHMA) CEO Raj Kannan on Q4 2020 Results - Earnings Call Transcript
08:34pm, Thursday, 04'th Mar 2021
Chiasma, Inc. (CHMA) CEO Raj Kannan on Q4 2020 Results - Earnings Call Transcript
Chiasma (CHMA) Reports Q4 Loss, Lags Revenue Estimates
06:12pm, Thursday, 04'th Mar 2021
Chiasma (CHMA) delivered earnings and revenue surprises of 8.57% and -17.75%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Chiasma Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update
04:01pm, Thursday, 04'th Mar 2021
Phased launch of MYCAPSSA® progressing with 2020 net product revenue of $1.1 million
Chiasma to Report Fourth Quarter 2020 Results on March 4
08:00am, Thursday, 25'th Feb 2021
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
Chiasma: Undervalued Despite Approval And Market Potential Of MYCAPSSA
08:00am, Monday, 22'nd Feb 2021
Chiasma: Undervalued Despite Approval And Market Potential Of MYCAPSSA
Chiasma Announces Hiring of John Doyle as Chief Financial Officer
07:00am, Tuesday, 19'th Jan 2021
Appointment provides extensive commercial-stage public company financial leadership experience Appointment provides extensive commercial-stage public company financial leadership experience
Chiasma Provides Corporate Update and Previews Expected 2021 Milestones
04:01pm, Wednesday, 06'th Jan 2021
MYCAPSSA ® launch in US continuing to gain traction with physicians, patients, and payers
Chiasma Trades At A Big Discount To Fair Value With Mycapssa On The Market
05:25pm, Monday, 07'th Dec 2020
Chiasma launched its first product, Mycapssa, on August 31, 2020. Mycapssa is the first product utilizing Chiasma's proprietary technology platform that enables oral version of previously injection-on
Revisiting Chiasma
06:48am, Wednesday, 02'nd Dec 2020
Today, we revisit Chiasma for the first time in over a year. This promising small-cap name recently posted some encouraging trial results and has seen a big recent insider purchase by its CEO.
Chiasma to Participate in Two Investor Conferences in December
08:00am, Monday, 23'rd Nov 2020
NEEDHAM, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize ora
